Skip to NavigationSkip to content

AstraZeneca's Calquence shows strength in most common adult leukaemia

Published on 06/06/19 at 10:26am

AstraZeneca has unveiled new Phase 3 data for Calquence (acalabrutinib) in treatment-naïve chronic lymphocytic leukaemia, showing that the drug met its primary endpoint when used in combination with obinutuzumab.

The data showed that Calquence use led to a “statistically-significant and clinically-meaningful improvement” in progression-free survival (PFS) compared to chemotherapy-based chlorambucil and obinutuzumab combo treatment, meeting its primary endpoint early

The study also met its secondary endpoint, improving PFS by a “statistically-significant and clinically-meaningful” margin compared to compared to a regimen of chemotherapy and obinutuzumab.

While specifics of the data were not revealed, AZ confirmed it would be presenting the full results at an upcoming medical meeting.

“These findings confirm the superiority of Calquence as a monotherapy and also in combination over standard-of-care treatments for chronic lymphocytic leukaemia,” commented José Baselga, AZ’s Executive Vice President, Oncology R&D.

The positive results from both the ELEVATE-TN and ASCEND trials will serve as the foundation for regulatory submissions later this year.”

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches